Clinical trial · Interventional
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
NCT04017455CI-TRIAL-00090772TARZANactive not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atezolizumab | Drug | Atezolizumab | ALIAS |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- bevacizumab and atezolizumab
- description
- 1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
- interventionNames
- Drug: Atezolizumab
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- clinical complete and near-complete response rate
- timeFrame
- 12 weeks post-radiotherapy
- description
- response rate will be assessed by MRI and endoscopy
Secondary outcomes (2)
- measure
- incidence of adverse events following treatment (safety)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * signed informed consent * patients age 18 years and older * histologically confirmed adenocarcinoma of the rectum * intermediate risk rectal cancer or low risk distal rectal cancer Exclusion Criteria: * evidence of metastatic disease * prior radiation therapy for disease under study * prior treatment with CD137 agonists or immune checkpoint blockade therapies * current or recent use of acetylsalicylic acid * history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding * significant auto-immune disease
References
Publications (0)
Data not yet available
No reference posted for this study.